Dear Editor:

The assessment of periportal fibrosis is of major importance in determining strategies, prognosis and risk for complications in schistosomiasis mansoni. For the last 2 decades, abdominal ultrasound has been used as the gold standard for the evaluation of liver fibrosis in schistosomiasis mansoni, but the sensitivity of hepatic biopsy has been shown to have low sensitivity in diagnosing advanced schistosomiasis.

However, ultrasound has disadvantages: 1. it is expensive; 2. it takes several months of training for the examiner to learn and apply WHO’s protocol for ultrasound in schistosomiasis; 3. it is a subjective procedure and, thence, examiner-dependent. It would be of interest to find a non-invasive, simpler routine laboratory test, to accurately evaluate liver fibrosis in schistosomiasis mansoni.

In the last 5 years several non-invasive indexes have been proposed for predicting the degree of fibrosis in viral hepatitis. The aspartate aminotransferase to platelet ratio index (APRI) was found to exhibit a high degree of accuracy in identifying presence of significant fibrosis and cirrhosis in patients with chronic hepatitis. APRI is obtained using the following formula:

$$\text{APRI} = \frac{\text{AST level/ULN}}{\text{Platelet counts (10^3/mm}^3\text{)}} \times 100$$

where AST is the value of aspartate aminotransferase measured in serum by a routine technique, ULN stands for upper limit of normal for aspartate aminotransferase, divided by blood platelet count, times 100.

We applied APRI and blood platelet count in 47 patients with hepatosplenomegaly confirmed by ultrasound (Group 1) and in 15 controls with hepatointestinal schistosomiasis (Group 2). APRI (mean ± SD) was 1.72 ± 1.20 and 0.34 ± 0.22 for groups 1 and 2, respectively (p = 0.00). The area under the receiver operating characteristic curve (AUC – ROC) was 0.96 [95% confidence interval (CI), 0.92 – 1.01]. For significant fibrosis, an APRI threshold of 0.44 was 96% sensitive and 85% specific. APRI was able to differentiate the degree of fibrosis: values for absent, light, moderate, and intense fibrosis were 0.34 ± 0.22, 1.38 ± 0.51, 1.74 ± 1.53 and 1.96 ± 0.94, respectively (p = 0.00).

Blood platelet counts (mm$^3$) were 60,426 ± 39,285 and 194,646 ± 97,768 for groups 1 and 2, respectively (p = 0.00). The AUC – ROC was 0.96 (95% CI, 0.91 – 1.01). For significant fibrosis, a platelet count threshold of 108,500/mm$^3$ was 91% sensitive and 85% specific. Platelet count also differentiated the degree of fibrosis. Platelets for absent, light, moderate, and intense fibrosis were 194,646 ± 97,768, 72,800 ± 24,289, 61,601 ± 43,721 and 44,114 ± 18,861, respectively (p = 0.00).

We conclude that APRI and blood platelet count are promising, inexpensive, non-invasive markers of liver fibrosis in schistosomiasis mansoni and also help to define the degree of liver involvement. A comprehensive study, with a larger number of patients, is under way to confirm these preliminary results.

REFERENCES


José Roberto Lambertucci, Luciana Cristina dos Santos Silva and Carlos Maurício Antunes